Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.800
+0.080 (4.65%)
At close: Jun 4, 2026, 4:00 PM EDT
1.790
-0.010 (-0.56%)
After-hours: Jun 4, 2026, 5:31 PM EDT
Chemomab Therapeutics Stock Forecast
CMMB's stock price has decreased by -66.42% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 analysts polled by S&P Global, Chemomab Therapeutics stock has a consensus rating of "Buy" and an average price target of $15. The average 1-year stock price forecast is 733.33% higher than the current stock price, while the lowest is $5.00 (+177.78%) and the highest is $25 (+1,288.89%).
Price Target: $15 (+733.33%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Chemomab Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $5 | Buy | Maintains | $5 | +177.78% | May 19, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $25 | Buy | Maintains | $25 | +1,288.89% | May 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.02
from -1.41
EPS Next Year
-0.03
from -0.02
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | ||
| Avg | n/a | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.02 | ||
| Avg | -0.02 | ||
| Low | -0.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.